TOPICAL Oral Therapies for type 2 Diabetes Day – 28th Sept 2022

Overview of type 2 diabetes

• To review the pathophysiology of type 2 diabetes

• To understand the methods and criteria for diagnosis type 2 diabetes
• To explore the impact of clinical inertia on patient outcomes and the importance of early treatment optimisation

• To recognise the differences between compliance, adherence and concordance and to understand the features of concordant patient consultations

• Oral therapies for patients with type 2 diabetes

• Discuss the considerations when choosing a treatment to meet the needs and circumstances of individual patients

• Review the standard oral therapies used in the treatment of type 2 diabetes

• Understand the sites of action for the different oral drug classes and be aware of the prescribing considerations including renal function and hepatic disease

• Consider different goals of treatment and evaluate how different oral therapies can help to achieve these goals

Oral therapies for patients with type 2 diabetes 

• Discuss the considerations when choosing a treatment to meet the needs and circumstances of individual patients

• Review the standard oral therapies used in the treatment of type 2 diabetes

• Understand the sites of action for the different oral drug classes and be aware of the prescribing considerations including renal function and hepatic disease

• Consider different goals of treatment and evaluate how different oral therapies can help to achieve these goals

Introducing CRM: the relationship between cardiovascular, renal and metabolic systems in type 2 diabetes

• Explore the interconnected relationship between conditions of the CRM system across type 2 diabetes
• Understand the wider impact and increased risks associated with having one or more conditions affecting the CRM system
• Consider the unmet clinical need related to CRM morbidity and mortality in patients with type 2 diabetes
• Understand how clinical guidance for type 2 diabetes has been updated to reflect the results of positive cardiovascular outcome trials
• Reflect on the overall goals of treatment and individualised care for patients with type 2 diabetes